Key result
The CYP2C19*2 gene polymorphism was significantly associated with recurring ischemic stroke in patients taking clopidogrel after acute ischemic cerebrovascular disease (OR 13.23).
Why the study?
Does the presence of CYP2C19 or P2Y12 gene polymorphisms increase the risk of recurring ischemic stroke in patients taking clopidogrel for acute ischemic cerebrovascular disease?
Population
51 patients who began prophylactic clopidogrel 75 mg/day due to acute ischemic cerebrovascular disease in…
Comparison
Presence of CYP2C19 or P2Y12 gene polymorphisms… vs Absence of CYP2C19 or P2Y12 gene polymorphisms…
Design
Cohort
Follow-up
at least 1 year
Authors
Loading...
Should not yet change clopidogrel use or prompt genotyping; leaves open need for prospective trials.
Cohort (n=51)
No
Does the presence of CYP2C19 or P2Y12 gene polymorphisms increase the risk of recurring ischemic stroke in patients taking clopidogrel for acute ischemic cerebrovascular disease?
Odds Ratio: 13.23 (95% CI 6.45–27.11)
Absolute Event Rate: 66.66% vs 13.54%
p-value: p=<0.0001
The CYP2C19 *2 gene polymorphism is associated with a significantly increased risk of recurrent ischemic stroke in patients taking clopidogrel after an acute ischemic cerebrovascular event.
Şen et al. (2014) conducted a cohort in Acute ischemic cerebrovascular disease (n=51). CYP2C19*2 gene polymorphism vs. Wild type CYP2C19*1 allele was evaluated on Recurring ischemic cerebrovascular disease (OR 13.23, 95% CI 6.45-27.11, p=<0.0001). The CYP2C19*2 gene polymorphism was significantly associated with recurring ischemic stroke in patients taking clopidogrel after acute ischemic cerebrovascular disease (OR 13.23).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: